@article{TLCR3201,
author = {Robert Pirker},
title = {Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {3},
number = {5},
year = {2014},
keywords = {},
abstract = {Adjuvant chemotherapy has been established as a standard for patients with completely resected non-small cell lung cancer (NSCLC). Adjuvant chemotherapy increased the 5-year survival rates by 4% to 15% within randomized trials and, based on a meta-analysis of five cisplatin-based trials, by 5.4%. Adjuvant chemotherapy consists of a cisplatin-based doublet, preferentially cisplatin plus vinorelbine. Future improvements in outcome of adjuvant therapy are expected by customized chemotherapy and the integration of targeted therapies or immunotherapy.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/3201}
}